RxDoctor Payments Data

Michael Gasman, MD

Pain Medicine · Chico, CANPI 1851461248

Payments from drug & device makers

$5,442in general payments, 2019–2025

Across 280 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$378
  • Zynex Medical, Inc.$342
  • AbbVie$224
  • Collegium Pharmaceutical, Inc.$206
  • Relievant Medsystems, Inc.$197
  • plus $770 from 16 others

What the payments were for

  • Food & beverage$5,442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,442 in reported general payments places this provider in the 70th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$808,521
Medicare patients
340
Services billed
10,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl70$69,888
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,535$44,430
Nucynta ErTapentadol Hcl22$29,034
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen452$14,957
Morphine Sulfate ErMorphine Sulfate325$10,436
Pregabalin117$9,867
Xtampza ErOxycodone Myristate12$8,429
ButransBuprenorphine12$7,513
Lidocaine25$7,488
Buprenorphine Hcl157$6,128
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$6,079
Fentanyl68$5,912
Buprenorphine20$5,871
Oxycodone Hcl272$5,385
Gabapentin205$3,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$206$37,46334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 pain medicine providers in California.

Other pain medicine in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →